Tesamorelin 5mg + Ipamorelin 5mg (10mg Blend)

Tesamorelin + Ipamorelin 10 mg blend

Buy Tesamorelin + Ipamorelin blend with 5 mg of each peptide and 10 mg total labeled material per vial. This research blend is supplied as lyophilized powder in one boxed 3 mL vial.

• Tesamorelin: 5 mg per vial
• Ipamorelin: 5 mg per vial
• Total blend: 10 mg per vial

A two-component formulation with equal labeled mass

The mixture has a 1:1 mass ratio. That does not mean it contains equal numbers of Tesamorelin and Ipamorelin molecules; their molecular sizes differ. Use the supplied chemical forms when calculating molar amounts.

The CJC-1295 NO DAC + Ipamorelin blend also has a 10 mg total, but contains a different GHRH-related partner. Matching total milligrams does not make the formulations interchangeable. For a separate-component comparison, see Tesamorelin 5 mg and Ipamorelin 5 mg.

Distinct peptide classes and research evidence

Tesamorelin is a growth hormone-releasing hormone (GHRH) analog. In Knoop and colleagues’ analytical study, mass spectrometry distinguished Tesamorelin from other GHRH-related materials. That identification method concerns defined reference analytes; it does not authenticate this finished blend.

Ipamorelin is a pentapeptide secretagogue. Raun and colleagues investigated growth-hormone release and selectivity in rat pituitary cells and animal models. Those findings describe the endpoints and models tested.

The two references address different questions. Neither tests the 5 mg + 5 mg mixture or establishes synergy. A blend experiment needs suitable component comparisons to distinguish the response to each ingredient from the combined response.

Review the certificate of analysis and product files

Open COA & Documents and match the product and lot. Check identity separately from purity, and whether the analytical record quantifies both components. A single purity percentage or combined weight does not confirm each labeled amount.

For handling and storage, follow documentation applicable to this mixture. The vial’s 3 mL capacity is separate from peptide content and does not specify a liquid volume or preparation protocol.